問卷

TPIDB > Principal Investigator

Principal Investigator


Taichung Veterans General Hospital (在職)

Division of Dermatology

Division of Rheumatology

Division of General Internal Medicine

Taipei Veterans General Hospital (在職)

Division of General Internal Medicine

更新時間:2023-09-19

謝佳偉
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

83Cases

2011-01-01 - 2011-12-31

Phase IV

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2023-05-01 - 2028-10-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting3Sites

Recruiting5Sites

2021-08-01 - 2025-02-04

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting3Sites

Recruiting2Sites

2022-01-12 - 2027-12-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting5Sites

2024-12-02 - 2030-12-09

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2024-09-01 - 2026-12-31

Phase II

xxxxxx
  • Condition/Disease

    xxxxxx

  • Test Drug

    amlitelimab

Participate Sites
2Sites

Recruiting2Sites

2024-01-15 - 2031-06-30

Phase III

A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjögren’s syndrome
  • Condition/Disease

    Hughes syndrome

  • Test Drug

    VAY736/ianalumabVAY736/ianalumab

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

2022-12-14 - 2026-01-01

Phase III

Active
A multi-center, randomized, double-blind, active-controlled, therapeutic confirmatory, phase III study to compare and evaluate the efficacy and safety of Epaminurad with Febuxostat in gout patients
  • Condition/Disease

    gout

  • Test Drug

    Epaminurad

Participate Sites
13Sites

Not yet recruiting1Sites

Recruiting12Sites

2007-04-01 - 2011-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2021-10-01 - 2023-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting2Sites

Recruiting1Sites